Immunovant, Inc. (IMVT)
Chart Events
Performance Outlook
| Previous Close | 20.28 |
| Open | 32.29 |
| Bid | 34.72 x 1000 |
| Ask | 35.04 x 800 |
| Day's Range | 32.13 - 37.26 |
| 52 Week Range | 4.49 - 37.26 |
| Volume | |
| Avg. Volume | 1,088,757 |
| Market Cap | 4.556B |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | Nov 02, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.92 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IMVT
Related Research
- Immunovant, Inc.Daily – Vickers Top Buyers & Sellers for 08/17/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
Motley FoolThese 2 Biotech Stocks Are Bucking a Down Market Tuesday
For instance, Monday's trading session gave market participants some optimism about how the economy could weather difficult times, but based on Tuesday morning's stock index futures movements, it's just difficult to build lasting positive momentum. Based on current futures levels, stocks looked poised to give back much of Monday's gains at the open on Tuesday morning. Both Immunovant (NASDAQ: IMVT) and Roivant Sciences (NASDAQ: ROIV) are relatively small players in biotech right now, but the latest news on one candidate treatment had investors feeling better about their long-term prospects.
- GlobeNewswire
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage
- GlobeNewswire
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will report initial IMVT-1402 Phase 1 results on Tuesday, September 26, 2023. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. To participate in the conference call, please register in advance here. To access the live a
